Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010) in comparison to placebo, as an add-on treatment to metformin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GetGoal-M-Asia (NCT01169779)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 35 sites in China, Hong Kong and 2 more
- Volunteers
- 391 people
- Sponsor
- Sanofi
Type 2 Diabetes
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.
- Trial name
- NCT00757588
- Testing
- Saxagliptin, 5 mg + insulin
- Where
- 80 sites in United States, Canada and 8 more
- Volunteers
- 455 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
This study aims to assess how glimepiride affects the recovery from hypoglycemia in participants with type 2 diabetes mellitus. The primary objective is to estimate the time taken by participants to recover from hypoglycemia to…
- Trial name
- NCT01614769
- Testing
- Glimepiride 2 mg, Glimepiride 4 mg, Hypoglycemic Clamp
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
Almond Butter and Fasting Glucose
A two-period randomized crossover study will be conducted to determine the effect of almond butter as an evening snack on fasting blood glucose in adults with type 2 diabetes, not taking insulin.
- Trial name
- NCT03826472
- Testing
- Almond Butter
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Penn State University
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells.
- Trial name
- NCT00025883
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects
Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine)…
- Trial name
- NCT02981966
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight…
- Trial name
- NCT01029886
- Testing
- exenatide once weekly, liraglutide
- Where
- 108 sites in Argentina, Australia and 19 more
- Volunteers
- 912 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy
- Trial name
- NCT04465877
- Testing
- JTT-662
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Shionogi Inc.
Diabetes Mellitus, Type 2
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control…
- Trial name
- NCT02409329
- Testing
- REACH, Helpline and A1c results, REACH + FAMS
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Diabetes
Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)
Background: Metformin is a pill youth with type 2 diabetes take. It can cause side effects like diarrhea and upset stomach. Researchers want to see if a fiber supplement can help decrease these side effects.
- Trial name
- NCT04209075
- Testing
- Biomebliss, Metformin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Metabolic Syndrome
P20 Extending Sleep to Reverse Metabolic Syndrome
This pilot study will test the acceptability and feasibility of a sleep extension intervention in community-dwelling, short-sleeping, racially/ethnically diverse middle-aged adults with MetS.
- Trial name
- NCT03596983
- Testing
- Sleep Intervention, Week 2 Intervention
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Type 2 Diabetes Mellitus
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
The purpose of this study is to examine the effect of exenatide, an anti-diabetes medication, on liver fat and blood levels of proteins that influence liver fat.
- Trial name
- NCT01432405
- Testing
- Exenatide, Pioglitazone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 2
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.
- Trial name
- NCT01408888
- Testing
- LY2189265, Sitagliptin
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study for Patients With Type 2 Diabetes Mellitus
A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT00804986
- Testing
- LY2428757
- Where
- 60 sites in United States, Austria and 9 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
QR-Bromocriptine as an add-on treatment to insulin and metformin in the management of type 2 diabetes will result in improved glycemic control, reduced exogenous insulin requirement, increased lean fat mass and improved…
- Trial name
- NCT01474018
- Testing
- QR-bromocriptine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 2
ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study
This is a 16-week, single center, randomized, double-blind, active-controlled, parallel-group, Phase 3b efficacy and safety study of simultaneous administration of saxagliptin 5 mg plus dapagliflozin 10 mg once daily (QD)…
- Trial name
- NCT02613897
- Testing
- Saxagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- AWARD-JPN (NCT04809220)
- Testing
- Dulaglutide, Oral antihyperglycemics
- Where
- 44 sites in Japan
- Volunteers
- 591 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1
The objective of this protocol is to answer the questions: 1) Are financial incentives layered upon nurse education and home telemonitoring superior to nurse education and home telemonitoring alone in improving metabolic control…
- Trial name
- FINANCE-DM (NCT04203173)
- Testing
- FINANCE-DM, Active Comparator
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- State University of New York at Buffalo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.